Table 2.
Recommendations for the symptomatic control of motor complications in PD. Only the highest level of recommendation available is provided.
| Recommen- dations | Type of motor complicatons |
||
|---|---|---|---|
| Wearing-off | Peak-dose dyskinesias | Unpredictable on–off | |
| MDS | Pergolide, pramipexole, ropinirole, apomorphine, selegiline, rasagiline, entacapone, tolcapone | Amantadine | No data |
| EFNS | Entacapone, selegiline, rasagiline, pramipexole, ropinirole, subcutaneous apomorphine | Amantadine, clozapine | Oral dispersible levodopa formulations for delayed on (low level) |
| AAN | Entacapone, rasagiline | Amantadine | No data |
| NICE | Levodopa, nonergot dopamine agonists, entacapone, MAO-I | Amantadine, continuous subcutaneous apomorphine | Intermittent apomorphine |
MAO-I, monoamine oxidase isoenzyme type B inhibitors; MDS, Movement Disorders Society; EFNS, European Federation of Neurological Societies; AAN, American Academy of Neurology; NICE, National Institute for Clinical Excellence.